Clinical Trials Logo

Urinary Tract Infections clinical trials

View clinical trials related to Urinary Tract Infections.

Filter by:

NCT ID: NCT06050148 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections

FMT-UTI
Start date: August 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study investigates Faecal microbiota transplantation (FMT) in prevention of recurrent urinary tract infections (UTIs) caused either by sensitive E. coli or ESBL-E. coli.

NCT ID: NCT06035601 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

EHR-integrated rUTI Texting Platform

Urotrust
Start date: March 7, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare a texting platform to usual care for managing recurrent urinary tract infections (UTI). The main question it aims to answer is: • can a texting platform that integrates symptom triage and prevention education reduce the rate of unnecessary antibiotics for recurrent UTIs as compared to usual care? Participants enrolled onto the texting platform will: • receive evidence-based clinical guidance for the management of symptoms of UTI and receive educational videos on how to prevent UTIs. An important secondary outcome is to determine if the texting platform improves self-efficacy for the management of recurrent UTI.

NCT ID: NCT06004739 Recruiting - Infectious Disease Clinical Trials

Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection

A-DONUT
Start date: April 2024
Phase: N/A
Study type: Interventional

Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.

NCT ID: NCT05967130 Recruiting - Clinical trials for Urinary Tract Infections

Treatment Chronic UTI Post Kidney Transplant

Start date: July 1, 2023
Phase: Phase 3
Study type: Interventional

Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.

NCT ID: NCT05905055 Recruiting - Clinical trials for Acute Pyelonephritis

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Integral-2
Start date: September 22, 2023
Phase: Phase 3
Study type: Interventional

This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.

NCT ID: NCT05895578 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection.

PROBUTI
Start date: June 21, 2023
Phase: N/A
Study type: Interventional

Urinary tract infections (UTIs) are the most common bacterial infections in women. 50% of women experiencing at least one UTI in their lifetime with an annual prevalence of 0.5-0.7%. An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strains on the urinary tract microbiota in participants with recurrent urinary tract infection (rUTI). The study duration will be 6 and a half months, including 6 months product intake. Participants will be randomly assigned to one of the three study groups: control group with placebo administration, probiotic administration group (1 dose) and probiotic administration group (2 doses).

NCT ID: NCT05887908 Recruiting - Clinical trials for Acute Pyelonephritis

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

Integral-1
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).

NCT ID: NCT05880602 Recruiting - Clinical trials for Urinary Tract Infection

Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

This study investigates whether the oral intake of a nettle and cranberry complex capsule may prevent recurrent urinary tract infection (rUTI). Participants will be aged between 30 - 75 years of age, with confirmed diagnosis of UTI status. The participants will be assessed for several parameters and asked to take 2 nettle and cranberry complex capsules twice daily for 8 weeks. The parameters will include international prostate symptoms score (IPSS), overactive bladder symptom score (OABSS), international consultation on incontinence questionnaire - overactive bladder (ICIQ-OAB), 3-day bladder diary (3dBD), and urine routine.

NCT ID: NCT05860231 Recruiting - Quality of Life Clinical Trials

Comparative Study Between Foley and T-Control® Catheter in Patients With Long-term Catheterization

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This is a comparative, randomized, controlled pilot study. The main objective of this study is to evaluate the efficacy, comfort, and patient experience in people with long-term bladder catheterization with T-Control® versus patients with a conventional Foley-type catheter.

NCT ID: NCT05826990 Recruiting - Clinical trials for Complicated Urinary Tract Infection

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.